Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL693967 | 0.98 | EPHX2 (0.43) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL11850495 | 0.83 | CYP1A2 (0.50) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL190928 | 0.81 | CYP1A2 (0.48) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL8947886 | 0.79 | LMNA (0.55) | CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL191353 | 0.79 | LMNA (0.55) | CYP1A2TDP1EPHX2EPHX1 | |
| SCHEMBL12036175 | 0.79 | CYP1A2 (0.46) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL5184241 | 0.79 | MAPT (0.38) | — | |
| SCHEMBL18711893 | 0.79 | CYP1A2 (0.46) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL18812726 | 0.77 | CYP1A2 (0.44) | CYP1A2TDP1EPHX2EPHX1KDM4E | |
| SCHEMBL14627318 | 0.77 | CYP1A2 (0.44) | CYP1A2TDP1EPHX2EPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518019-B | Preparation method of paliperidone palmitate intermediate | 江苏豪森药业集团有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-111518019-A | Preparation method of paliperidone palmitate intermediate | 江苏豪森药业集团有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-101921224-B | 1-(3-aminopropyl) piperazine-4-aminoamide compound as well as preparation method and application thereof | INST BIOENGINEERING AMMS | 2012-01-18 | — | — | CN | claimed |
| CN-101921224-A | 1-(3-aminopropyl) piperazine-4-aminoamide compound as well as preparation method and application thereof | INST BIOENGINEERING AMMS | 2010-12-22 | — | — | CN | claimed |
| EP-4729059-A2 | THIAZOLO [5,4-B] PYRIDINE MALT-1 INHIBITORS | Abbvie Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | RAREFIED BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4547658-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119855821-A | Thiazolo [5,4-b ] pyridine MALT-1 inhibitors | 艾伯维公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250084099-A1 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS | ABBVIE INC (US) | 2025-03-13 | — | — | US | disclosed |
| US-4342870-A | SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-08-03 | — | — | US | disclosed |
| EP-0037265-A1 | 3-(1-piperidinylalkyl)-4H-pyrido(1,2-a)pyrimidin-4-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-10-07 | — | — | EP | disclosed |
| US-4151285-A | ANTICONVULSANT, ANTI-ANXIETY AGENTS | A. H. ROBINS COMPANY, INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4110459-A | ANALGESIC | AMERICAN HOECHST CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4101663-A | ANTIHYPERTENSIVES | AMERICAN HOECHST CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
| US-4054570-A | NEUROLEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4046900-A | TRANQUILIZERS, HYPOTENSIVES, ANALGESICS | AMERICAN HOECHST CORPORATION (US) | 1977-09-06 | — | — | US | disclosed |
| US-3992546-A | 4-Piperidinobutyrophenones as neuroleptics | CIBA-GEIGY CORPORATION (US) | 1976-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | MALT1, SQSTM1, PPP1R10 | CYP1A2 3396/4885TDP1 1025/4885EPHX2 4423/4885 |
| US-20250084099-A1 | THIAZOLO[5,4-B]PYRIDINE MALT-1 INHIBITORS | MALT1, PTP4A1, AMY1A | CYP1A2 457/4885TDP1 523/4885EPHX2 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.